Sarcopenia and age-related muscle loss

Strength falls two to three times faster than mass, and the scale will not tell you. What the condition is, how it is measured, what actually reverses it — and the honest limit of four days.

The short answer

Sarcopenia is the progressive loss of skeletal muscle mass and strength that comes with age. It is not a figure of speech and not a lifestyle complaint: it has a diagnostic definition, a set of measurement thresholds, and since 2016 an ICD-10 code of its own. It is also, as of today, the most consequential age-related change for which no drug is approved anywhere in the world. The one intervention with consistent evidence behind it is progressive resistance training with enough protein to support it.

That makes sarcopenia treatment in China — or anywhere — a narrower proposition than the marketing around longevity suggests. What a serious programme can do is measure where you actually are, using instruments most annual physicals leave out, read the muscle number against the bone number, and send you home with a loading plan precise enough to follow. On this island that work sits in the retreat’s Frame axis, and the numbers that drive it come out of the day-two screen.

What follows is the detail: why strength matters more than size, how the condition is actually measured, what the trial evidence does and does not support, where the island’s version sits, and the honest limit of four days.

Why strength, not size, is the thing that matters

The 2019 European consensus definition inverted the earlier model. Low muscle strength became the primary criterion; low muscle quantity or quality became the confirmation; poor physical performance became the marker of severity rather than of diagnosis. The reason is blunt — strength predicts falls, fracture, hospital admission, loss of independence and mortality more reliably than mass does.

The two also decline at different rates. Muscle mass falls by roughly half a percent to one percent a year from the fifth decade. Strength falls two to three times faster, and explosive power — the ability to produce force quickly, which is what catches you when you trip — faster again. Because fat tends to occupy the space the muscle vacates, the number on the bathroom scale can hold steady across a decade in which a third of your strength has gone. “I haven’t put on weight” is not reassurance. It is the most common reason the condition goes unmeasured until something breaks.

How sarcopenia is actually measured

The sequence is screen, then strength, then quantity, then performance. None of it is exotic equipment; most of it is simply absent from a standard executive physical.

One caveat worth carrying into any clinic conversation: the cut-offs are population-specific. The European 2019 thresholds above are not the Asian Working Group’s 2019 values, which set grip at 28 kg for men and 18 kg for women and gait speed at 1.0 m/s. A grip figure quoted without its reference population is a number, not a diagnosis — and a programme assessing a European guest against Asian thresholds, or the reverse, will reach the wrong conclusion in the borderline range where the conclusion matters most.

Muscle and bone decline together, and almost nobody screens both

The same DXA acquisition that yields appendicular lean mass yields bone mineral density. Measuring one and not the other is a wasted scan, because the two losses are coupled: declining muscle means declining mechanical load on bone, and declining bone strength means a fall is likelier to end in a fracture. The overlap has a name, osteosarcopenia, and the risk it carries is not additive but multiplicative — weak muscles make the fall more likely and weak bones make the fall more expensive.

For post-menopausal women the two curves steepen at the same time, which is the single strongest argument for measuring both at one sitting rather than discovering the bone number years later in an emergency department.

What the evidence supports, and what it does not

Supported. Progressive resistance training is the intervention with the strongest and most consistent evidence base for older adults: substantial gains in strength, smaller and less consistent gains in everyday function, across a large body of randomised trials. The dose that appears in those trials is two or three sessions a week against a load that increases as you adapt, and the timescale to a measurable change is eight to twelve weeks, not days. Protein supports it: around 1.0 to 1.2 grams per kilogram of body weight a day for a healthy older adult, 1.2 to 1.5 during acute or chronic illness, distributed across meals rather than loaded into dinner. Correcting a genuine vitamin D deficiency is worth doing; supplementing someone already replete does not build muscle.

Not supported. No drug is approved for sarcopenia in any jurisdiction, and the failures are instructive rather than incidental. Agents targeting the myostatin and activin pathway, bimagrumab the most studied of them, reliably add lean mass in trials and have repeatedly failed to deliver the matching improvement in walking speed or function. That is the cleanest demonstration available that mass is not the endpoint — and the clearest warning about any programme that measures its success in kilograms of lean tissue. Testosterone in older men raises lean mass with a modest strength effect and a cardiovascular question that is not settled; growth hormone has no place here at all. Both are prescription decisions for your own physician.

Where this sits in a longevity programme in Hainan: the Frame axis

The retreat’s wellness half runs on a six-axis system, and 筋骨 · Frame is the strength-and-posture axis. It is driven by numbers rather than by how you say you feel: body composition and bone density out of the day-two precision screen set the targets, and a Milon-quantified strength assessment turns the starting load into a figure rather than an impression. What is delivered alongside it is holographic and VR-guided training, used so that movement patterns are learned under supervision, and deep-tissue and fascia recovery work. The six axes are explained together in wellness retreats in China, and the four days they sit inside are set out hour by hour in what happens on a longevity retreat.

Two things are worth stating plainly about that. First, Frame is not automatic. The screen decides which two or three axes are yours, and for many guests the first one is not Frame but Flow or Mind — poor sleep is the most common finding and it undoes strength work faster than almost anything, which is why sleep retreats in China treats that axis on its own. Second, the Frame axis is a wellness programme. It is not a cell therapy, and the restrictions that govern the cell arm do not apply to it.

What four days can and cannot do

Four days cannot make you stronger. The biology does not move that fast, and the previous section gives the honest floor: eight to twelve weeks of progressive loading before a measurable change. Any provider implying otherwise is describing something other than muscle.

What four days can do is the part that is hard to arrange at home. Establish the baseline with instruments a standard physical omits — grip, chair-stand, appendicular lean mass, bone density, read together rather than separately. Find the asymmetries, which is where most of the useful information is, since a left-right strength difference is both a fall risk and the thing a generic programme will miss. Learn the movements correctly under supervision, because the home programme is only as good as the technique it inherits. And hand the file to someone: the written plan and the twelve-month follow-up are the mechanism by which week twelve gets re-measured rather than forgotten. The plan is the product; the four days are how it gets built.

Why the cell arm is not the answer to this

Under State Council Order No. 818, in force since 1 May 2026, cell and gene therapy in China is delivered as disease treatment: against a filed indication, in a licensed institution, to a patient a hospital panel has accepted, with outcome reporting. The rule and what it changed are set out on is stem cell therapy legal in China, and the point here is narrow — age-related muscle loss is not an indication you can buy a cell infusion for. A provider offering stem cells for sarcopenia is either operating outside the rule or describing a different product.

There is a real route, and it runs the other way round. If the screen finds something — a fracture-risk bone number, or a neurological, endocrine or inflammatory cause sitting behind weakness that was assumed to be ordinary ageing — that becomes a medical matter for the treating hospital’s specialists, and that is the path by which any treatment, cell or otherwise, is considered at all. Equally, a guest arriving with a diagnosis and a prescription from their own physician is in a different position from a healthy guest asking for an infusion. How that gate works, and who the panel declines, is covered in safety and regulation.

Who it suits, and who should not bother

What it costs

The four-day retreat that produces these numbers is offered from about $2,700 all-in, covering the screening battery, the specialist panel that reads it, the villa, meals, transfers and twelve months of follow-up. Anything the panel recommends beyond the retreat’s inclusions is quoted in writing by the hospital that would deliver it, which is why no programme price appears on this page. Comparable Alpine longevity programmes list at roughly $36,000 to $58,000 (2026 rates) for a week; what sits inside each of those figures, and how to compare them honestly, is unpacked in what a longevity programme in China costs.

Seven questions to ask any clinic about muscle and bone

What this page is not claiming

Nothing here is a promise of outcome, a diagnosis, or a substitute for your own physician. The thresholds quoted are published consensus figures and are reference points, not results. Candidacy for any programme on this island — and for anything at all in the cell arm — is determined by the treating hospital’s specialists after full diagnostics, and the strength and posture work described here is a wellness programme whose honest claim is that it measures carefully and hands you a plan you can follow.

Frequently asked

What is sarcopenia?

Sarcopenia is the progressive, age-related loss of skeletal muscle mass and, more importantly, of muscle strength. It is a recognised clinical condition, not a figure of speech: it carries an ICD-10 code (M62.84, added in 2016) and a diagnostic definition published by the European Working Group on Sarcopenia in Older People in 2019, which made low muscle strength the primary criterion and low muscle quantity the confirmation.

At what age does age-related muscle loss start?

Muscle mass begins to decline measurably from the fifth decade, at roughly half a percent to one percent a year. Strength falls two to three times faster than mass, and explosive power faster still. Because fat tends to replace the lost muscle, body weight can stay flat while a third of strength disappears, which is why a stable number on the bathroom scale is not reassurance.

How is sarcopenia diagnosed?

By measuring strength first. The usual sequence is a short screening questionnaire, then a hand-grip dynamometer or a five-times chair-stand test, then imaging to confirm muscle quantity, usually appendicular lean mass by DXA. Physical performance, most often gait speed, grades severity rather than establishing the diagnosis. Cut-offs differ by reference population: the European 2019 thresholds are grip strength under 27 kg for men and 16 kg for women, while the Asian Working Group's 2019 values are 28 kg and 18 kg, so a number quoted without its reference population is not a diagnosis.

Can age-related muscle loss be reversed?

Strength can be substantially regained at almost any age, and muscle mass partially. Progressive resistance training is the only intervention with consistent evidence behind it, and the timescale is weeks to months: eight to twelve weeks of two or three loaded sessions a week is the usual floor for a measurable change. Adequate protein, about 1.0 to 1.2 grams per kilogram of body weight a day for a healthy older adult and 1.2 to 1.5 during illness, supports the training but does not replace it.

Is there a drug for sarcopenia?

No drug is approved for sarcopenia in any jurisdiction. Agents acting on the myostatin and activin pathway, bimagrumab among them, reliably increase lean mass in trials and have repeatedly failed to produce the matching gain in walking speed or function, which is the clearest available demonstration that mass is not the endpoint. Testosterone in older men raises lean mass with a modest strength effect and an unsettled cardiovascular question; it is a prescription decision for your own physician, not something to buy from a retreat.

Can stem cell therapy treat muscle loss or sarcopenia in China?

No. Under State Council Order No. 818, in force since 1 May 2026, cell and gene therapy in China is delivered as disease treatment, against a filed indication, to a patient a hospital panel has accepted. Age-related muscle loss is not an indication you can buy a cell infusion for, and no honest provider will offer one. The strength and posture work described on this page is not a cell programme and carries no such restriction.

How much does sarcopenia assessment in China cost?

The four-day retreat that produces the body-composition, strength and bone numbers is offered from about $2,700 all-in, covering the screening battery, the specialist panel that reads it, the villa, meals, transfers and twelve months of follow-up. Anything the panel recommends beyond the retreat's inclusions is quoted in writing by the hospital that would deliver it, which is why no programme price appears here. Comparable Alpine longevity programmes list at roughly $36,000 to $58,000 (2026 rates) for a week.

Can four days actually change muscle loss?

Four days cannot make you stronger; the biology will not move that fast. What four days can do is establish the baseline most annual physicals skip, find the left-right asymmetries and the bone number, teach the movements under supervision so the home programme is correct rather than approximate, and hand the whole thing to a care manager for the following year. Any provider promising strength gains inside a week is describing something other than muscle.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.